Actionnariat et activité des initiés pour Protagonist Therapeutics, Inc. (PTGX): transactions des initiés, déclarations de trading du Sénat et de la Chambre américaine et actions en circulation. Suivez comment dirigeants et politiciens négocient le titre.
Prix
| Prix | $142.84 |
| Capitalisation | $9.2B |
| Bourse | NASDAQ |
| Pays | US |
Transactions d'Initiés Récentes
| Date | Initié | Type | Actions | Valeur |
|---|---|---|---|---|
| 2026-09-09 | PATEL DINESH V PH D | M-Exempt | 63,548 | $1.4M |
| 2026-09-08 | PATEL DINESH V PH D | M-Exempt | 54,174 | $1.2M |
| 2026-09-10 | PATEL DINESH V PH D | M-Exempt | 7,278 | $157K |
| 2026-09-10 | PATEL DINESH V PH D | S-Sale | 7,278 | $1.0M |
| 2026-09-08 | PATEL DINESH V PH D | S-Sale | 54,174 | $7.9M |
| 2026-09-09 | PATEL DINESH V PH D | S-Sale | 63,548 | $9.3M |
| 2026-09-08 | PATEL DINESH V PH D | M-Exempt | 54,174 | $1.2M |
| 2026-09-09 | PATEL DINESH V PH D | M-Exempt | 63,548 | $1.4M |
| 2026-09-10 | PATEL DINESH V PH D | M-Exempt | 7,278 | $157K |
| 2026-09-03 | PATEL DINESH V PH D | G-Gift | 510 |
Bilan (10 ans)
| Année | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Trésorerie | $21.1M | $106.0M | $82.2M | $33.0M | $117.4M | $123.7M | $125.7M | $186.7M | $97.2M | $128.4M |
| Placements à Court Terme | $56.5M | $38.0M | $46.6M | $100.0M | $188.5M | $203.2M | $111.6M | $154.9M | $321.7M | $439.0M |
| Créances | $2.2M | $1.8M | $4.6M | $6.8M | $3.8M | $5.3M | $52000 | $10.3M | $168.5M | $4.5M |
| Stocks | -$7.7M | -$8.7M | $2.1M | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Courants | $83.2M | $150.9M | $137.5M | $145.3M | $315.6M | $340.7M | $243.1M | $355.6M | $591.6M | $577.6M |
| Immobilisations Corporelles | $562000 | $879000 | $861000 | $7.7M | $6.4M | $6.7M | $4.6M | $2.1M | $12.6M | $11.7M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Incorporels | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Actifs Totaux | $94.0M | $163.7M | $139.5M | $154.9M | $324.5M | $347.7M | $247.9M | $358.0M | $744.7M | $669.9M |
| Dettes Fournisseurs | $1.2M | $1.3M | $5.7M | $2.8M | $3.1M | $1.6M | $3.6M | $772000 | $1.6M | $5.3M |
| Dette à Court Terme | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $510000 | $2.3M |
| Passifs Courants | $6.4M | $42.6M | $26.2M | $35.4M | $40.2M | $44.0M | $31.2M | $21.3M | $47.4M | $45.4M |
| Dette à Long Terme | 0 | 0 | 0 | $9.8M | 0 | 0 | 0 | 0 | 0 | 0 |
| Passifs Totaux | $6.4M | $43.1M | $27.0M | $75.0M | $44.9M | $47.7M | $32.3M | $21.3M | $69.4M | $55.2M |
| Réserves | -$64.6M | -$101.5M | -$140.5M | -$217.7M | -$283.8M | -$409.4M | -$536.8M | -$615.7M | -$340.5M | -$470.7M |
| Capitaux Propres | -$64.6M | -$101.5M | -$140.5M | $80.0M | $279.6M | $300.0M | $215.6M | $336.7M | $675.3M | $614.7M |
| Dette Totale | 0 | 0 | 0 | $17.0M | $6.0M | $5.9M | $3.7M | $1.1M | $10.9M | $10.3M |
| Dette Nette | -$77.6M | -$144.0M | -$128.9M | -$116.0M | -$299.9M | -$321.0M | -$233.7M | -$340.5M | -$408.0M | -$557.0M |
| Fonds de Roulement | $76.8M | $108.4M | $111.3M | $109.9M | $275.4M | $296.7M | $211.9M | $334.3M | $544.2M | $532.1M |
Santé financière
| Dette / Capitaux propres | 0.02 |
| Ratio de liquidité | 12.71 |
| Piotroski F-Score | 3 |
| Altman Z-Score | 59.63 |
Rentabilité
| Rentabilité des capitaux propres | -21.17% |
| Rentabilité du capital investi | -25.23% |
| Rentabilité des actifs | -19.43% |
| Marge brute | 97.34% |
| Marge opérationnelle | -343.63% |
| Marge nette | -282.83% |
Entreprises liées: ACLX · AKRO · ALKS · CRNX · IMVT · KYMR · NAMS
Explorer le secteur: Healthcare · Biotechnology
Plus de sections de PTGX: Vue d'ensemble · Financiers · Valorisation · Statistiques · Estimations · Technique · Actualités · Événements
Découvrir plus: Radar — signaux d'actions sous-évaluées · Académie d'Investissement — apprenez à analyser les actions